Tapentadol extended release for chronic pain patients

Area of Science:

• Pharmacology
• Pain Management
• Clinical Trials

Background:

• Chronic pain significantly impacts quality of life and healthcare costs.
• Current long-term pharmacologic options for chronic pain are limited, with opioids often causing noncompliance due to side effects.
• A need exists for long-term analgesics with a favorable benefit/risk ratio.

Purpose of the Study:

• To evaluate the efficacy and safety of tapentadol extended release (ER) for noncancer chronic pain.
• To compare tapentadol ER with placebo and controlled-release oxycodone in randomized trials.
• To assess the benefit/risk profile of tapentadol ER for chronic pain management.

Main Methods:

• A literature search was conducted for randomized controlled trials of tapentadol ER in noncancer chronic pain patients.
• Databases searched included PubMed, MEDLINE, EMBASE, and Google Scholar.
• Key terms used were "tapentadol," "prolonged release," "extended release," and "chronic pain."

Main Results:

• Six randomized controlled studies were identified, analyzing conditions like low back pain, osteoarthritis, and diabetic peripheral neuropathy.
• Tapentadol ER demonstrated significant pain reduction compared to placebo and comparable efficacy to oxycodone CR.
• Tapentadol ER showed a superior safety profile to oxycodone CR, with fewer and less severe side effects, particularly gastrointestinal issues, leading to lower discontinuation rates.

Conclusions:

• Tapentadol ER, with its dual mechanism of action and extended release, provides efficacy similar to strong controlled-release opioids.
• Improved gastrointestinal tolerability of tapentadol ER correlates with higher patient compliance.
• Tapentadol ER presents a viable alternative to conventional strong opioids for managing chronic pain.